Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by nozzpackon Nov 14, 2023 8:03am

327 Views

Post# 35733804

Peer based Valuation Is $12

I use Biostent ( T.RX ) which is a very close sibling of CPH.

Great balance sheet.....but not as good as as CPH.
Similar drug suites...but not as good as CPH as RX shows no growth .

RX trades at 20 times net earnings and CPH trades at about 7 times.

There is absolutely no reason for this disparity..

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals